Table 3 Categorical Analysis of PVR gene expression and serum levels in relation to clinical and laboratory parameters in multiple myeloma patients (n = 50)
Parameter | PVR gene expression | PVR serum level | ||||
|---|---|---|---|---|---|---|
Low (≤3) (n= 25) | High (>3) (n=25) | Significance Test (p-value) | Low (≤124) (n=26) | High (>124) (n=24) | Significance test (p-value) | |
Sex | ||||||
 Male | 11 (44.0%) | 12 (48.0%) | χ2 = 0.08 (0.777) | 11 (42.3%) | 12 (50.0%) | χ2 = 0.29 (0.586) |
 Female | 14 (56.0%) | 13 (52.0%) | 15 (57.7%) | 12 (50.0%) | ||
eGFR | ||||||
 <60 | 16 (64.0%) | 16 (64.0%) | χ2 = 0.0 (1.000) | 18 (69.2%) | 14 (58.3%) | χ2 = 0.64 (0.423) |
 >60 | 9 (36.0%) | 9 (36.0%) | 8 (30.8%) | 10 (41.7%) | ||
M Protein type |  | 1 (5.9%) 16 (94.1%) | χ2 = 0.07 (1.000) | 1 (4.5%) 21 (95.5%) | 2 (10.0%) 18 (90.0%) | χ2 = 0.47 (0.598) |
 IGA  IGG | 2 (8.0%) 23 (92.0%) | |||||
t(4:14) exchange |  |  | 20 (76.9%) 6 (23.1%) | 12 (50.0%) 12 (50.0%) | χ2 = 3.93(0.048)* | |
 Negative  Positive | 21 (84.0%) 4 (16.0%) | 11 (44.0%) 14 (56.0%) | χ2 = 8.68 (0.003)* | |||
TP53 mutation |  | 19 (76.0%) 6 (24.0%) | χ2 = 6.82 (0.002)* | 24 (92.3%) 2 (7.7%) | 20 (83.3%) 4 (16.7%) | χ2 = 0.95 (0.409) |
 Negative  Positive | 25 (100.0%) 0 (0.0%) | |||||
ISS Staging  Stage I  Stage II  Stage III | 11 (44.0%) 14 (56.0%) 0 (0.0%) | 0 (0.0%) 0 (0.0%) 25 (100.0%) | χ2 = 50.0 (<0.001)* | 11 (42.3%) 6 (23.1%) 9 (34.6%) | 0 (0.0%) 8 (33.3%) 16 (66.7%) | χ2 =13.18 (0.001)* |
Serum Amylase |  | ` 2 (8.0%) 23 (92.0%) | χ2 =35.28(<0.001)* | 16 (61.5%) 10 (38.5%) | 9 (37.5%) 15 (62.5%) | χ2 = 2.88 (0.089) |
 Low  High | 23 (92.0%) 2 (8.0%) | |||||
Urine IGFBP-7 | 12 (48.0%) 13 (52.0%) | χ2 = 0.080 (0.777) | 15 (57.7%) 11 (42.3%) | 10 (41.7%) 14 (58.3%) | χ2 = 1.28(0.258) | |
 Low  High | 13 (52.0%) 12 (48.0%) | |||||
Urine TIMP-2 | 2 (8.0%) 23 (92.0%) | χ2 = 2.083 (0.490) | 1 (3.8%) 25 (96.2%) | 1 (4.2%) 23 (95.8%) | χ2 = 0.00 (1.000) | |
 Low  High | 0 (0.0%) 25 (100.0%) | |||||